International Assets Investment Management LLC Acquires 1,414,556 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

International Assets Investment Management LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 76,051.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,416,416 shares of the medical research company’s stock after buying an additional 1,414,556 shares during the quarter. International Assets Investment Management LLC owned approximately 0.37% of Thermo Fisher Scientific worth $876,152,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Monte Financial Group LLC grew its position in Thermo Fisher Scientific by 2.7% during the third quarter. Monte Financial Group LLC now owns 2,213 shares of the medical research company’s stock valued at $1,369,000 after buying an additional 58 shares during the period. Courier Capital LLC grew its position in Thermo Fisher Scientific by 798.9% during the third quarter. Courier Capital LLC now owns 8,405 shares of the medical research company’s stock valued at $5,199,000 after buying an additional 7,470 shares during the period. Sterling Investment Counsel LLC grew its position in Thermo Fisher Scientific by 10.6% during the third quarter. Sterling Investment Counsel LLC now owns 2,169 shares of the medical research company’s stock valued at $1,342,000 after buying an additional 207 shares during the period. Greenleaf Trust grew its position in Thermo Fisher Scientific by 0.9% during the third quarter. Greenleaf Trust now owns 12,406 shares of the medical research company’s stock valued at $7,674,000 after buying an additional 115 shares during the period. Finally, Commerzbank Aktiengesellschaft FI boosted its position in shares of Thermo Fisher Scientific by 25.7% in the third quarter. Commerzbank Aktiengesellschaft FI now owns 133,420 shares of the medical research company’s stock worth $82,530,000 after purchasing an additional 27,318 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the transaction, the executive vice president now owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the transaction, the executive vice president now owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Joseph R. Holmes sold 860 shares of the company’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $611.03, for a total value of $525,485.80. Following the transaction, the chief accounting officer now directly owns 1,814 shares in the company, valued at approximately $1,108,408.42. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock valued at $14,094,292 over the last ninety days. 0.34% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on TMO shares. Barclays dropped their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research report on Wednesday. JPMorgan Chase & Co. upped their price target on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a research report on Monday, October 14th. They issued a “buy” rating and a $680.00 price target for the company. Raymond James upped their price target on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Finally, Stephens began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price target for the company. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $655.50.

Thermo Fisher Scientific Trading Down 1.7 %

Shares of NYSE TMO opened at $576.49 on Thursday. The business’s 50 day moving average is $607.04 and its two-hundred day moving average is $584.39. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $627.88. The stock has a market capitalization of $220.22 billion, a P/E ratio of 35.76, a PEG ratio of 3.75 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. During the same period in the previous year, the firm posted $5.15 earnings per share. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.